AstraZeneca PLC (AZN)vsPark Dental Partners, Inc. Common Stock (PARK)
AZN
AstraZeneca PLC
$185.95
-0.83%
HEALTHCARE · Cap: $282.69B
PARK
Park Dental Partners, Inc. Common Stock
$18.64
-9.56%
HEALTHCARE · Cap: $85.61M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 24256% more annual revenue ($60.44B vs $248.15M). AZN leads profitability with a 17.2% profit margin vs -0.9%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
PARK
Hold37
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for PARK.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Earnings expanding 526.0% YoY
Generating 2.7B in free cash flow
Areas to Watch
Moderate valuation
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -18.6% — below average capital efficiency
Distress zone — elevated risk
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : PARK
The strongest argument for PARK centers on EPS Growth, Free Cash Flow.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : PARK
The primary concerns for PARK are Market Cap, Return on Equity, Altman Z-Score. Debt-to-equity of 2.35 is elevated, increasing financial risk.
Key Dynamics to Monitor
AZN profiles as a mature stock while PARK is a turnaround play — different risk/reward profiles.
AZN is growing revenue faster at 12.5% — sustainability is the question.
PARK generates stronger free cash flow (2.7B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 37/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Park Dental Partners, Inc. Common Stock
HEALTHCARE · MEDICAL CARE FACILITIES · USA
Park Dental Partners, Inc. is a dental resource organization that offers business support services to dentists throughout Minnesota and Wisconsin. The company is headquartered in Roseville, Minnesota.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?